Bone Therapeutics Statistics
Bone Therapeutics (0R55) Stock Statistics & Valuation Metrics
Total Valuation
Bone Therapeutics has a market cap or net worth of EUR 1.31M. The enterprise value is EUR 3.78M.
- Market Cap
- EUR 1.31M
- Enterprise Value
- EUR 3.78M
Share Statistics
Bone Therapeutics has 652,862,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 652,862,300
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Bone Therapeutics’s return on equity (ROE) is 1.26 and return on invested capital (ROIC) is -127.14%.
- Return on Equity (ROE)
- 1.26
- Return on Assets (ROA)
- -3.01
- Return on Invested Capital (ROIC)
- -127.14%
- Return on Capital Employed (ROCE)
- 1.12
- Revenue Per Employee
- 45.25K
- Profits Per Employee
- -2.40M
- Employee Count
- 12
- Asset Turnover
- 0.06
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Bone Therapeutics is -5.65. Bone Therapeutics’s PEG ratio is 0.06.
- PE Ratio
- -5.65
- PS Ratio
- 43.36
- PB Ratio
- 3.27
- Price to FCF
- -6.02
- Price to Operating Cash Flow
- -6.04
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, Bone Therapeutics had revenue of 543.00K and earned -28.78M in profits. Earnings per share was -0.21.
- Revenue
- 543.00K
- Gross Profit
- 543.00K
- Operating Income
- -7.04M
- Pretax Income
- -29.03M
- Net Income
- -28.78M
- EBITDA
- -6.80M
- Earnings Per Share (EPS)
- -0.21
Cash Flow
In the last 12 months, operating cash flow was -2.37M and capital expenditures 12,000, giving a free cash flow of -1.95M billion.
- Operating Cash Flow
- -2.37M
- Free Cash Flow
- -1.95M
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Bone Therapeutics pays an annual dividend of EUR 0.29, resulting in a dividend yield of ―
- Dividend Per Share
- EUR 0.29
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -16.60%
- Earnings Yield
- -17.70%
Stock Price Statistics
- Beta
- -0.01
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Bone Therapeutics upcoming earnings date is Apr 29, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Apr 29, 2027
- Ex-Dividend Date
- Mar 15, 2022
Financial Position
Bone Therapeutics as a current ratio of 0.12, with Debt / Equity ratio of -122.91%
- Current Ratio
- 0.12
- Quick Ratio
- 0.12
- Debt to Market Cap
- 3.27
- Net Debt to EBITDA
- -4.13
- Interest Coverage Ratio
- -1.18
Taxes
In the past 12 months, Bone Therapeutics has paid -7,000 in taxes.
- Income Tax
- -7,000
- Effective Tax Rate
- 0.00
Enterprise Valuation
Bone Therapeutics EV to EBITDA ratio is -13.52, with an EV/FCF ratio of -15.94.
- EV to Sales
- 114.74
- EV to EBITDA
- -13.52
- EV to Free Cash Flow
- -15.94
- EV to Operating Cash Flow
- -15.98
Balance Sheet
Bone Therapeutics has EUR 816.00K in cash and marketable securities with EUR 26.79M in debt, giving a net cash position of -EUR 25.98M billion.
- Cash & Marketable Securities
- EUR 816.00K
- Total Debt
- EUR 26.79M
- Net Cash
- -EUR 25.98M
- Net Cash Per Share
- -EUR 0.04
- Tangible Book Value Per Share
- -EUR 0.12
Margins
Gross margin is 77.44%, with operating margin of -871.43%, and net profit margin of -767.29%.
- Gross Margin
- 77.44%
- Operating Margin
- -871.43%
- Pretax Margin
- -1146.24%
- Net Profit Margin
- -767.29%
- EBITDA Margin
- -848.87%
- EBIT Margin
- -871.43%

